We are a leading global provider of vital molecular information that guides the management of life-threatening cancers.

Telo Genomics Corp. is a Canada-based molecular diagnostics company. The Company has developed a telomere-based platform with applications in multiple cancers and Alzheimer's disease. The TeloView® platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability - these data are used to identify specific disease mechanisms, predict disease risks, and determine effective treatments. Telo’s proprietary technology have been studied in 160+ peer-reviewed publications and in 30+ clinical studies with more than 3,000 patients. The company's lead application, TeloView-SMM, has been validated in collaboration with the Mayo Clinic.